C4 Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

C4 Therapeutics CEO'su Andrew Hirsch, Sep2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 3.79M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.9% maaş ve 83.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.071% ine doğrudan sahiptir ve bu hisseler $ 324.49K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 7.3 yıldır.

Anahtar bilgiler

Andrew Hirsch

İcra Kurulu Başkanı

US$3.8m

Toplam tazminat

CEO maaş yüzdesi	16.9%
CEO görev süresi	4.2yrs
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	7.3yrs

Son yönetim güncellemeleri

Recent updates

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Oct 02

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

Aug 09

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Aug 03

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

CEO Tazminat Analizi

Andrew Hirsch'un ücretlendirmesi C4 Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$105m
Jun 30 2024	n/a	n/a	-US$108m
Mar 31 2024	n/a	n/a	-US$126m
Dec 31 2023	US$4m	US$639k	-US$132m
Sep 30 2023	n/a	n/a	-US$135m
Jun 30 2023	n/a	n/a	-US$140m
Mar 31 2023	n/a	n/a	-US$131m
Dec 31 2022	US$3m	US$614k	-US$128m
Sep 30 2022	n/a	n/a	-US$107m
Jun 30 2022	n/a	n/a	-US$99m
Mar 31 2022	n/a	n/a	-US$95m
Dec 31 2021	US$952k	US$580k	-US$84m
Sep 30 2021	n/a	n/a	-US$80m
Jun 30 2021	n/a	n/a	-US$82m
Mar 31 2021	n/a	n/a	-US$73m
Dec 31 2020	US$21m	US$168k	-US$66m

Tazminat ve Piyasa: Andrew 'nin toplam tazminatı ($USD 3.79M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.40M ).

Tazminat ve Kazançlar: Andrew şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Andrew Hirsch (53 yo)

4.2yrs

Görev süresi

US$3,790,099

Tazminat

Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andrew Hirsch	CEO, President & Director	4.2yrs	US$3.79m	0.071% $ 324.5k
Kenneth Anderson	Co-Founder	no data	US$111.41k	0.45% $ 2.1m
Leonard M. Reyno	Chief Medical Officer	1.3yrs	US$1.96m	0.013% $ 58.9k
Nathanael Gray	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kendra Adams	CFO & Treasurer	1.2yrs	Veri yok	0.021% $ 97.3k
Mark Mossler	Chief Accounting Officer	1.2yrs	Veri yok	0.0021% $ 9.7k
Paige Mahaney	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Courtney Solberg	Senior Manager of Investor Relations	no data	Veri yok	Veri yok
Jolie Siegel	Chief Legal Officer & Corporate Secretary	4.3yrs	US$3.38m	0.016% $ 74.4k
Kelly Schick	Chief People Officer	3.8yrs	Veri yok	0.016% $ 74.4k
Isabel Chiu	Senior Vice President of Strategic Alliances & Business Development	8.7yrs	Veri yok	Veri yok
Christopher Nasveschuk	Senior Vice President of Chemistry	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: CCCC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Andrew Hirsch	CEO, President & Director	4.1yrs	US$3.79m	0.071% $ 324.5k
Kenneth Anderson	Co-Founder	8.9yrs	US$111.41k	0.45% $ 2.1m
Nathanael Gray	Co-Founder & Member of Scientific Advisory Board	8yrs	Veri yok	Veri yok
Bruce Downey	Lead Independent Director	8.9yrs	US$157.91k	0.69% $ 3.2m
Christopher Bowden	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Christopher Kirk	Member of Scientific Advisory Board	8yrs	Veri yok	Veri yok
Ross Levine	Member of Scientific Advisory Board	7.3yrs	Veri yok	Veri yok
Ronald H. Cooper	Independent Chairman	less than a year	Veri yok	Veri yok
Ryan Corcoran	Member of Scientific Advisory Board	5.2yrs	Veri yok	Veri yok
Scott Armstrong	Member of Scientific Advisory Board	7.3yrs	Veri yok	Veri yok
Utpal Koppikar	Independent Director	2.7yrs	US$126.41k	0.0080% $ 36.6k
Beni Wolf	Member of Clinical Advisory Board	no data	Veri yok	Veri yok

7.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CCCC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).

C4 Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

C4 Therapeutics, Inc. Announces Executive Changes

C4 Therapeutics, Inc. Announces Board Changes

C4 Therapeutics, Inc. Announces Board and Committee Changes

C4 Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors

C4 Therapeutics, Inc. Appoints Mary Christian as Senior Vice President, Regulatory

Recent updates

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics, Inc. Announces Executive Changes

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

C4 Therapeutics, Inc. Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept from Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at European Society for Medical Oncology Congress 2024

C4 Therapeutics, Inc. Announces Board Changes

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

New minor risk - Profitability

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics, Inc. Announces Board and Committee Changes

Consensus EPS estimates upgraded to US$1.59 loss, revenue downgraded

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

Price target decreased by 30% to US$11.88

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

C4 Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Consensus revenue estimates increase by 12%

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Price target increased by 8.0% to US$16.00

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 13% to US$15.50

C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.

C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

New major risk - Share price stability

C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors

Price target decreased by 13% to US$16.20

Price target decreased by 12% to US$16.40

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Price target decreased by 31% to US$13.11

C4 Therapeutics, Inc. Announces Upcoming Data Presentations for CFT8634 and CFT7455

Price target increased by 7.4% to US$20.40

Consensus revenue estimates decrease by 27%, EPS upgraded

Price target decreased by 9.3% to US$17.23

C4 Therapeutics, Inc. Appoints Mary Christian as Senior Vice President, Regulatory

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

C4 Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for CFT8919

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell Small Cap Comp Value Index

C4 Therapeutics, Inc. Appoints Leonard (Len) Reyno as Chief Medical Officer, Effective July 10, 2023

C4 Therapeutics, Inc. announced that it expects to receive $25 million in funding from Betta Pharmaceuticals Co., Ltd.

Price target decreased by 8.1% to US$19.23

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

Consensus revenue estimates decrease by 16%, EPS upgraded

Price target decreased by 30% to US$14.83

Price target increased by 10% to US$23.73

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

C4 Therapeutics, Inc. Announces Executive Changes

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC(Tm) Degrader, in BRAF V600 Mutant Solid Tumors

Price target decreased to US$23.46

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

C4 Therapeutics, Inc. Appoints Laura Bessen and Donna Grogan to its Board of Directors

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 2000 Growth Index

C4 Therapeutics, Inc. Announces Alain J. Cohen Withdrawal as a Director Nominee for Re-Election At the 2022 Annual Meeting

C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-Null Tumors